Quarterly report
Open the filing on sec.gov
Bicycle Therapeutics plc (BCYC)
Nasdaq: BCYC · Pharmaceutical Preparations · Cambridge, GB · filing with the SEC since 2018
The companyfiscal 2025, as filed
Revenue$72.6M+105.8%
Net income-$219M-29.5%
Earnings per share$-3.16-9.0%
Operating cash flow-$250M-51.6%
Cash$629M-28.6%
Debtn/a
Shareholders’ equity$610M-23.1%
Shares, diluted69.3M+19.0%
Return on equity-35.9%
The recordfrom its filings
Filings in 202683
Newest filingOct 29 · 10-Q
Annual reportMar 17, 2026
Quarterly reportOct 29, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$500,000
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $83.5MNet income -$142MCash from operations -$175Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.